ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Serum D-Dimer, Glycated Serum Protein, and HbA1c Levels in Predicting Macrosomia in Gestational Diabetes Mellitus.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the predictive efficacy of serum D-Dimer (D-D), Glycated Serum Protein (GSP), and HbA1c levels for macrosomia in Gestational Diabetes Mellitus (GDM). Methods: A retrospective analysis was conducted on 224 pregnant women diagnosed with GDM from January 2021 to July 2024. Based on neonatal birth weight, 112 women were assigned to the macrosomia group, and 112 women with normal birth weight infants were assigned to the normal group. Serum levels of D-D, GSP, and HbA1c were measured and compared between the two groups. Binary regression analysis and ROC curve analysis were performed to assess the relationship between these biomarkers and the risk of macrosomia. Results: The macrosomia group had significantly higher levels of D-D (4.90 vs 2.98 mg/L), GSP (3.49 vs 3.07 μmol/L), HbA1c (7.49% vs 5.85%), and HOMA-IR (4.35 vs 3.84) compared to the normal group (all p<0.001). Multivariate regression analysis revealed that D-Dimer (OR = 2.374), Glycated Serum Protein (GSP, OR = 31.890), and HbA1c (OR = 2.482) were significantly associated with the occurrence of macrosomia, even after adjusting for confounders including BMI. ROC curve analysis demonstrated that the combined detection of D-D, GSP, and HbA1c had an AUC of 0.9241, with a sensitivity of 83.93% and specificity of 86.61%, providing higher diagnostic accuracy than single biomarkers. Conclusion: Serum D-D, GSP, and HbA1c levels are significant factors in predicting macrosomia in GDM pregnancies. The combined use of these markers can improve diagnostic accuracy and serve as a valuable tool for early identification of high-risk pregnancies in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.